Structure Therapeutics' Aleniglipron Phase 2b Data in Nature Medicine Redraws the Oral GLP-1 Efficacy Map

Structure Therapeutics' Aleniglipron Phase 2b Data in Nature Medicine Redraws the Oral GLP-1 Efficacy Map

On August 10, 2026, Structure Therapeutics (NASDAQ: GPCR) announced the publication of landmark results from its Phase 2b ACCESS clinical trial of aleniglipron (GSBR-1290) in Nature Medicine. Simultaneously presented at a major medical conference, the data establishes aleniglipron as a highly potent, once-daily oral small-molecule GLP-1 receptor agonist with "best-in-class" potential, directly challenging the Eli Lilly and Novo Nordisk injectable duopoly.

The randomized, double-blind, placebo-controlled Phase 2b trial evaluated aleniglipron in adults living with obesity or overweight with at least one weight-related co-morbidity. Over a 36-week treatment period, participants demonstrated progressive and clinically meaningful weight loss across all evaluated doses:

• 120 mg dose: Achieved an absolute weight loss of 12.1% from baseline, translating to a -11.3% placebo-adjusted weight reduction (LS mean).
• 90 mg dose: Achieved an absolute weight loss of 10.7% from baseline, translating to a -9.8% placebo-adjusted weight reduction.
• 45 mg dose: Achieved an absolute weight loss of 9.0% from baseline, translating to a -8.2% placebo-adjusted weight reduction.

In comparison, the placebo group experienced only a -0.5% weight change from baseline.

Why Small-Molecule GLP-1s Matter to Investors

Currently, the multi-billion-dollar obesity market is dominated by peptide-based injectables (Novo Nordisk's Wegovy and Eli Lilly's Zepbound) and Novo's peptide-based oral Wegovy pill. However, peptide-based oral formulations suffer from low bioavailability, complex dosing requirements (such as taking them on an empty stomach with a small sip of water and waiting 30 minutes), and massive manufacturing scale bottlenecks.

In contrast, aleniglipron is a non-peptide small-molecule drug. Designed using structure-based drug discovery, small molecules offer:

1. Chemical stability and ease of manufacturing: They can be produced using standard chemical synthesis rather than complex biologic fermentation, dramatically reducing production costs and eliminating supply chain bottlenecks.
2. Superior patient convenience: They can be taken as a standard daily pill without strict fasting or water restrictions, improving long-term patient adherence.¹
3. Favorable tolerability: The ACCESS trial demonstrated a favorable safety and tolerability profile. Crucially, the data showed that patients could successfully restart treatment or continue to titrate up after a temporary dose interruption without experiencing worsened gastrointestinal side effects.

With Eli Lilly aggressively advancing its own oral small-molecule GLP-1, orforglipron (Foundayo), aleniglipron's strong Phase 2b results position Structure Therapeutics as a premier independent competitor. Structure is preparing to advance aleniglipron into Phase 3 trials, which will test higher doses (up to 240 mg in the ACCESS II trial) to push efficacy even closer to the 15%–20% benchmark set by injectables.

Verbatim Quotes

• Nature Medicine Phase 2b ACCESS Study Publication:

"By week 36, average body-weight change from baseline reached −9.0 percent in the 45 milligrams group, -10.7 percent in the 90 milligrams group and -12.1 percent in the 120 milligrams group. The placebo group had a -0.5 percent change." — ScienceDaily Report on Nature Medicine Study

• Structure Therapeutics Press Release:

"The Phase 2b ACCESS clinical trial of aleniglipron for the treatment of people living with obesity and/or overweight... demonstrated clinically meaningful weight reductions with a favorable safety and tolerability profile that does not worsen after aleniglipron reintroduction following dose interruption." — Structure Therapeutics Press Release via BioSpace